CompletedNCT05655507
Zuranolone safety and drug levels in adolescents with depression
About this title
Read the official source — NCT05655507This study evaluated the safety of Zuranolone for people with depression.
Medication studyAges 12–17United States
Understand this study
What did researchers investigate?
This study evaluated the safety of Zuranolone for people with depression.
Who was this study for?
Listed age limits: 12 years to 17 years.
- Listed locations
- Atlanta and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: April 19, 2023
- Recruitment status
- Completed
- Enrollment listed in the registry
- 19
- Sponsor
- Biogen
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 12 Years to 17 Years
- Official registry ID
- NCT05655507
- Official title
Show the full official title
A Phase 1, Study to Evaluate the Pharmacokinetics and Safety of Zuranolone in Adolescents (12 to 17 Years of Age) With Major Depressive Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Atlanta · Decatur · Flowood
1 more locations
- Cincinnati
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the safety of Zuranolone for people with depression.
Who is behind this study?
The study sponsor is Biogen.
Did this study involve medication?
Yes. The study involved medication, including Zuranolone.
Who was this study for?
Listed age limits: 12 years to 17 years.
